Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Plasma Protease C1-inhibitor Treatment market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Plasma Protease C1-inhibitor Treatmentmarket, defines the market attractiveness level of Plasma Protease C1-inhibitor Treatment market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Plasma Protease C1-inhibitor Treatment industry, describes the types of Plasma Protease C1-inhibitor Treatment market, the applications of major players and the market size, and deeply analyzes the current situation of the global Plasma Protease C1-inhibitor Treatment market and the development prospects and opportunities of Plasma Protease C1-inhibitor Treatment industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Plasma Protease C1-inhibitor Treatment market in Chapter 13.
By Player:
CSL Behring LLC
Ionis Pharmaceuticals, Inc
Centogene AG
Pharming Technologies BV
BioCryst Pharmaceuticals
KalVista Pharmaceuticals, Inc
Takeda Pharmaceutical Company Limited
By Type:
C1-inhibitors
Kallikrein Inhibitor (Kalbitor)
By End-User:
Hospital Pharmacies
Independent Pharmacies and Outlets
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Plasma Protease C1-inhibitor Treatment Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Plasma Protease C1-inhibitor Treatment Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Plasma Protease C1-inhibitor Treatment Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Plasma Protease C1-inhibitor Treatment Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Plasma Protease C1-inhibitor Treatment Market Analysis and Outlook to 2022
-
7.1 Global Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
7.2 United States Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
7.3 Europe Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
7.4 China Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
7.5 Japan Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
7.6 India Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
-
7.7 South Korea Plasma Protease C1-inhibitor Treatment Consumption (2017-2022)
8 Region and Country-wise Plasma Protease C1-inhibitor Treatment Market Analysis and Outlook to 2028
-
8.1 Global Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
8.2 United States Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
8.3 Europe Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
8.4 China Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
8.5 Japan Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
8.6 India Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
-
8.7 South Korea Plasma Protease C1-inhibitor Treatment Consumption Forecast (2022-2028)
9 Global Plasma Protease C1-inhibitor Treatment Market Outlook by Types and Applications to 2022
-
9.1 Global Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global C1-inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Kallikrein Inhibitor (Kalbitor) Consumption and Growth Rate (2017-2022)
-
9.2 Global Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Independent Pharmacies and Outlets Consumption and Growth Rate (2017-2022)
10 Global Plasma Protease C1-inhibitor Treatment Market Outlook by Types and Applications to 2028
-
10.1 Global Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global C1-inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Kallikrein Inhibitor (Kalbitor) Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Independent Pharmacies and Outlets Consumption Forecast and Growth Rate (2022-2028)
11 Global Plasma Protease C1-inhibitor Treatment Import and Export Analysis (Top 5 Countries)
-
11.1 Global Plasma Protease C1-inhibitor Treatment Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Plasma Protease C1-inhibitor Treatment Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Plasma Protease C1-inhibitor Treatment Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Plasma Protease C1-inhibitor Treatment Market Competitive Analysis
-
14.1 CSL Behring LLC
-
14.1.1 CSL Behring LLC Company Details
-
14.1.2 CSL Behring LLC Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 CSL Behring LLC Plasma Protease C1-inhibitor Treatment Product and Service
-
14.2 Ionis Pharmaceuticals, Inc
-
14.2.1 Ionis Pharmaceuticals, Inc Company Details
-
14.2.2 Ionis Pharmaceuticals, Inc Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Ionis Pharmaceuticals, Inc Plasma Protease C1-inhibitor Treatment Product and Service
-
14.3 Centogene AG
-
14.3.1 Centogene AG Company Details
-
14.3.2 Centogene AG Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Centogene AG Plasma Protease C1-inhibitor Treatment Product and Service
-
14.4 Pharming Technologies BV
-
14.4.1 Pharming Technologies BV Company Details
-
14.4.2 Pharming Technologies BV Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Pharming Technologies BV Plasma Protease C1-inhibitor Treatment Product and Service
-
14.5 BioCryst Pharmaceuticals
-
14.5.1 BioCryst Pharmaceuticals Company Details
-
14.5.2 BioCryst Pharmaceuticals Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 BioCryst Pharmaceuticals Plasma Protease C1-inhibitor Treatment Product and Service
-
14.6 KalVista Pharmaceuticals, Inc
-
14.6.1 KalVista Pharmaceuticals, Inc Company Details
-
14.6.2 KalVista Pharmaceuticals, Inc Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 KalVista Pharmaceuticals, Inc Plasma Protease C1-inhibitor Treatment Product and Service
-
14.7 Takeda Pharmaceutical Company Limited
-
14.7.1 Takeda Pharmaceutical Company Limited Company Details
-
14.7.2 Takeda Pharmaceutical Company Limited Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Takeda Pharmaceutical Company Limited Plasma Protease C1-inhibitor Treatment Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Plasma Protease C1-inhibitor Treatment
-
Figure Plasma Protease C1-inhibitor Treatment Picture
-
Table Global Plasma Protease C1-inhibitor Treatment Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Plasma Protease C1-inhibitor Treatment Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Plasma Protease C1-inhibitor Treatment Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Plasma Protease C1-inhibitor Treatment Consumption by Country (2017-2022)
-
Figure United States Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Table Europe Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure China Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Japan Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure India Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure South Korea Plasma Protease C1-inhibitor Treatment Consumption and Growth Rate (2017-2022)
-
Figure Global Plasma Protease C1-inhibitor Treatment Consumption Forecast by Country (2022-2028)
-
Figure United States Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Plasma Protease C1-inhibitor Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global C1-inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Kallikrein Inhibitor (Kalbitor) Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Independent Pharmacies and Outlets Consumption and Growth Rate (2017-2022)
-
Figure Global C1-inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Kallikrein Inhibitor (Kalbitor) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Independent Pharmacies and Outlets Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Plasma Protease C1-inhibitor Treatment Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Plasma Protease C1-inhibitor Treatment Export by Region (Top 5 Countries) (2017-2028)
-
Table CSL Behring LLC (Foundation Year, Company Profile and etc.)
-
Table CSL Behring LLC Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table CSL Behring LLC Plasma Protease C1-inhibitor Treatment Product and Service
-
Table Ionis Pharmaceuticals, Inc (Foundation Year, Company Profile and etc.)
-
Table Ionis Pharmaceuticals, Inc Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ionis Pharmaceuticals, Inc Plasma Protease C1-inhibitor Treatment Product and Service
-
Table Centogene AG (Foundation Year, Company Profile and etc.)
-
Table Centogene AG Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Centogene AG Plasma Protease C1-inhibitor Treatment Product and Service
-
Table Pharming Technologies BV (Foundation Year, Company Profile and etc.)
-
Table Pharming Technologies BV Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pharming Technologies BV Plasma Protease C1-inhibitor Treatment Product and Service
-
Table BioCryst Pharmaceuticals (Foundation Year, Company Profile and etc.)
-
Table BioCryst Pharmaceuticals Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table BioCryst Pharmaceuticals Plasma Protease C1-inhibitor Treatment Product and Service
-
Table KalVista Pharmaceuticals, Inc (Foundation Year, Company Profile and etc.)
-
Table KalVista Pharmaceuticals, Inc Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table KalVista Pharmaceuticals, Inc Plasma Protease C1-inhibitor Treatment Product and Service
-
Table Takeda Pharmaceutical Company Limited (Foundation Year, Company Profile and etc.)
-
Table Takeda Pharmaceutical Company Limited Plasma Protease C1-inhibitor Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Takeda Pharmaceutical Company Limited Plasma Protease C1-inhibitor Treatment Product and Service
-
